vandetanib
Sign in to saveVandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumors of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase. The drug was developed by AstraZeneca who sold the rights to Sanofi in 2015.
Chemical data
- Formula
- C22H24BrFN4O2
- Molecular weight
- 475.4 g/mol
- IUPAC name
- N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
via PubChem
Research
1,152 papers- Vandetanib photoinduced cutaneous toxicities.Cutis · 2019
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.Endocrine-related cancer · 2024
- Vandetanib therapy in medullary thyroid cancer.Drugs of today (Barcelona, Spain : 1998) · 2012
- Vandetanib for the treatment of thyroid cancer: an update.Expert opinion on drug metabolism & toxicology · 2014
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- +474.107
Show 6 more facts
- P2175
- thyroid cancer
- P366
- medication
- P3493
- boxed warning
- P769
- fosphenytoin
via Wikidata · CC0
Article
8 sectionsContents
- Medical use
- Contraindications
- Adverse effects
- Interactions
- Pharmacology
- History
- Research
- References
Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumors of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase. The drug was developed by AstraZeneca who sold the rights to Sanofi in 2015.
==Medical use== Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in people with unresectable locally advanced or metastatic disease. Vandetanib is used to treat medullary thyroid cancer in adults who are ineligible for surgery.